Results 91 to 100 of about 3,323,629 (269)

Demographic characteristics of prostate cancer patients according to use of androgen deprivation therapy, radiotherapy, and radical prostatectomy.

open access: yes, 2020
Demographic characteristics of prostate cancer patients according to use of androgen deprivation therapy, radiotherapy, and radical prostatectomy.
Yu-Li Su (761278)   +5 more
core   +1 more source

Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer

open access: yesThe Prostate, EarlyView.
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain.
Meghana Yellanki   +6 more
wiley   +1 more source

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. [PDF]

open access: yes, 2015
We have previously reported that radiotherapy (RT) added to androgen-deprivation therapy (ADT) improves survival in men with locally advanced prostate cancer.
Parmar, MK   +54 more
core   +1 more source

Prognostic Value of MRI‐Derived Apparent Diffusion Coefficient in Intermediate‐Risk Prostate Cancer Treated With Definitive Radiotherapy

open access: yesThe Prostate, EarlyView.
ABSTRACT Background Intermediate‐risk prostate cancer (IR‐PCa) is a heterogeneous disease with variable clinical outcomes despite established risk classification. We evaluated whether pretreatment tumor apparent diffusion coefficient (ADC) derived from multiparametric MRI was associated with long‐term outcomes and provided additional prognostic ...
Cem Onal   +4 more
wiley   +1 more source

Where does fat regionally accumulate during androgen deprivation therapy?

open access: yes, 2018
Where does fat regionally accumulate during androgen deprivation ...
Trish Livingston (13098306)   +6 more
core  

Cost-effective analysis of supervised exercise training in men with prostate cancer previously treated with androgen deprivation therapy and radiation

open access: yes, 2019
Aim: Exercise for prostate cancer (PC) survivors has been shown to be effective in addressing metabolic function and associated comorbidities (eg, diabetes, cardiovascular disease, etc), as well as sarcopenia and significant functional impairment ...
Scuffham, Paul   +14 more
core   +1 more source

Evaluation of Time to Metastasis After Prostatectomy as a Prognostic Factor in Patients With Metachronous mHSPC: A Secondary Analysis of the SWOG‐1216 Phase 3 Trial

open access: yesThe Prostate, EarlyView.
ABSTRACT Background The prognostic significance of time to metastasis (TTM) following radical prostatectomy in patients with metachronous metastatic hormone‐sensitive prostate cancer (mHSPC) remains uncertain. We performed a secondary analysis of patient‐level data from the phase 3 SWOG 1216 randomized clinical trial to evaluate whether TTM is ...
Nicolas Sayegh   +15 more
wiley   +1 more source

Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway.

open access: yesPLoS ONE, 2019
Radiation therapy is often combined with androgen deprivation therapy in the treatment of aggressive localized prostate cancer. However, castration-resistant disease may not respond to testosterone deprivation approaches.
Konjeti R Sekhar   +3 more
doaj   +1 more source

Cardiovascular risk with androgen deprivation therapy

open access: yesInternational Journal of Clinical Practice, 2019
From the primary care perspective, many urologists and oncologists appear to be ignoring an FDA warning to assess patients' cardiovascular (CV) risk before instituting androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists.
openaire   +2 more sources

Does Androgen Deprivation Therapy Impact Subjective Cognitive Function in Men with Non-metastatic Prostate Cancer? [PDF]

open access: yes, 2016
Androgen-deprivation therapy is used to treat almost 50% of current prostate cancer patients. Despite slowing disease progression and prolonging survival, androgen-deprivation therapy is associated with numerous side effects.
Marzouk, Shireen
core   +1 more source

Home - About - Disclaimer - Privacy